[snips]
(MedPage Today) -- Breast cancer survivors had more than a 50% increase in the risk of recurrence if they were taking ACE inhibitors, a retrospective analysis of a large cohort study showed.
Concomitant use of a beta-blocker attenuated the breast cancer recurrence risk but was associated with a significantly higher overall mortality.
Beta-blocker use alone had a protective effect against breast cancer recurrence and cause-specific mortality, according to an article published online in Breast Cancer Research and Treatment.
Still, if you've been treated for early-stage breast cancer and are also taking an ACE inhibitor you may want to talk to the doctor who manages your cancer follow-up care about the possible link.
More: http://www.breastcancer.org/risk/new_research/20110422.jsp
The actual study:
Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort.
Ganz PA, Habel LA, Weltzien EK, Caan BJ, Cole SW.
Among 1,779 women, there were 292 BC recurrences, 174 BC deaths, and 323 total deaths. 23% were exposed to either a BB and/or an ACEi. These drugs were associated with older age, postmenopausal status, tamoxifen therapy, greater pre-diagnosis BMI, hypertension, and diabetes. In Cox proportional hazards models, ACEi exposure was associated with BC recurrence (HR 1.56, 95% CI 1.02, 2.39, P = 0.04), but not cause-specific or overall mortality. Combined ACEi and BB were associated with overall mortality (HR 1.94, 95% CI 1.22, 3.10, P = 0.01). BB exposure was associated with lower hazard of recurrence and cause-specific mortality. However, there was no evidence of a dose response with either medication. For recurrence and cause-specific mortality, BB combined with ACEi was associated with a lower HR for the outcome than when ACEi alone was used. These hypothesis generating findings suggest that BC recurrence and survival were associated with exposure to two commonly used classes of anti-hypertensive medications. These observations need to be confirmed and suggest that greater attention should focus on the potential role of these commonly used medications in BC outcomes.
http://www.ncbi.nlm.nih.gov/pubmed/21479924
(MedPage Today) -- Breast cancer survivors had more than a 50% increase in the risk of recurrence if they were taking ACE inhibitors, a retrospective analysis of a large cohort study showed.
Concomitant use of a beta-blocker attenuated the breast cancer recurrence risk but was associated with a significantly higher overall mortality.
Beta-blocker use alone had a protective effect against breast cancer recurrence and cause-specific mortality, according to an article published online in Breast Cancer Research and Treatment.
Still, if you've been treated for early-stage breast cancer and are also taking an ACE inhibitor you may want to talk to the doctor who manages your cancer follow-up care about the possible link.
More: http://www.breastcancer.org/risk/new_research/20110422.jsp
The actual study:
Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort.
Ganz PA, Habel LA, Weltzien EK, Caan BJ, Cole SW.
Among 1,779 women, there were 292 BC recurrences, 174 BC deaths, and 323 total deaths. 23% were exposed to either a BB and/or an ACEi. These drugs were associated with older age, postmenopausal status, tamoxifen therapy, greater pre-diagnosis BMI, hypertension, and diabetes. In Cox proportional hazards models, ACEi exposure was associated with BC recurrence (HR 1.56, 95% CI 1.02, 2.39, P = 0.04), but not cause-specific or overall mortality. Combined ACEi and BB were associated with overall mortality (HR 1.94, 95% CI 1.22, 3.10, P = 0.01). BB exposure was associated with lower hazard of recurrence and cause-specific mortality. However, there was no evidence of a dose response with either medication. For recurrence and cause-specific mortality, BB combined with ACEi was associated with a lower HR for the outcome than when ACEi alone was used. These hypothesis generating findings suggest that BC recurrence and survival were associated with exposure to two commonly used classes of anti-hypertensive medications. These observations need to be confirmed and suggest that greater attention should focus on the potential role of these commonly used medications in BC outcomes.
http://www.ncbi.nlm.nih.gov/pubmed/21479924